Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression

A new study published in JAMA Psychiatry, one of the world's most prestigious medical journals, has found that psilocybin may offer a promising treatment for major depression that hasn't responded to conventional medications. Treatment-resistant depression affects millions of people globally, and patients often exhaust standard options with limited success. The research documents both efficacy and acceptable safety profiles, adding to growing evidence that psychedelic compounds, long sidelined from medical research, could open new therapeutic pathways. This reflects a broader renaissance in clinical research around psychedelics—a field that had been largely dormant for decades.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton